Boston Life Sciences Announces Webcast Of 2006 Annual Meeting

HOPKINTON, Mass., Dec. 13 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. today announced that the Company will webcast the corporate presentation portion of its Annual Meeting of Stockholders. The meeting is being held on Thursday, December 14, 2006 at 1:00p.m. EST at the offices of Wilmer Cutler Pickering Hale & Dorr, 60 State Street, Boston, MA. The webcast is expected to begin at approximately 1:15p.m. EST and will be available on the Investor Relations section of the Company's website at http://www.bostonlifesciences.com. The event will be archived and available for replay through December 14, 2007.

About Boston Life Sciences, Inc.

Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinsonian Syndrome (PS) and Phase II clinical trials for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS programs include Inosine for the treatment of stroke, a DAT blocker for the treatment of Parkinson's disease and a second generation technetium-based molecular imaging agent for PS and ADHD. BLSI's current research collaborations include Harvard Medical School and Children's Hospital Boston.

Contact: Meredith Patin -- 508-497-2360 ext 239

Boston Life Sciences, Inc. mpatin@bostonlifesciences.com

Boston Life Sciences, Inc.

CONTACT: Meredith Patin of Boston Life Sciences, Inc., +1-508-497-2360,ext. 239, mpatin@bostonlifesciences.com

Back to news